F. Hoffmann-La Roche Ltd: Roche’s Tecentriq in combination with Abraxane improves outcomes as an initial treatment for people with PD-L1-positive metastatic triple-negative breast cancer

By Mein Vergleich Published 21. Oktober 2018 News

F. Hoffmann-La Roche Ltd / Roche’s Tecentriq in combination with Abraxane improves outcomes as an initial treatment for people with PD-L1-positive metastatic triple-negative breast cancer . Process…
FinanzNachrichten.de: Meistgelesene Nachrichten

Tags: Abraxane breast cancer Combination HoffmannLa improves initial metastatic Nachrichten outcomes PDL1positive people positive Roche Roche's Tecentriq treatment triplenegative with

Schreibe einen Kommentar Antworten abbrechen